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Abstract 
We compare several molecular fingerprint encodings for marketed, small molecule drugs, and assess how 
their rank order varies with the fingerprint in terms of the Tanimoto similarity to the most similar 
endogenous human metabolite as taken from Recon2. For the great majority of drugs, the rank order varies 
very greatly depending on the encoding used, and also somewhat when the Tanimoto similarity (TS) is 
replaced by the Tversky similarity. However, for a subset of such drugs, amounting to some 10 % of the set 
and a Tanimoto similarity of ~0.8 or greater, the similarity coefficient is relatively robust to the encoding 
used. This leads to a metric that, while arbitrary, suggests that a Tanimoto similarity of 0.75-0.8 or greater 
genuinely does imply a considerable structural similarity of two molecules in the drug-endogenite space. 
Although comparatively few (<10 % of) marketed drugs are, in this sense, robustly similar to an endogenite, 
there is often at least one encoding with which they are genuinely similar (e.g. TS > 0.75). This is referred to 
as the Take Your Pick Improved Cheminformatic Analytical Likeness or TYPICAL encoding, and on this basis 
some 66 % of drugs are within a TS of 0.75 to an endogenite.  
We next explicitly recognise that natural evolution will have selected for the ability to transport dietary 
substances, including plant, animal and microbial ‘secondary’ metabolites, that are of benefit to the host. 
These should also be explored in terms of their closeness to marketed drugs. We thus compared the TS of 
marketed drugs with the contents of various databases of natural products. When this is done, we find that 
some 80 % of marketed drugs are within a TS of 0.7 to a natural product, even using just the MACCS 
encoding. For patterned and TYPICAL encodings, 80 % and 98 % of drugs are within a TS of 0.8 to (an 
endogenite or) an exogenous natural product. This implies strongly that it is these exogeneous (dietary and 
medicinal) natural products that are more to be seen as the ‘natural’ substrates of drug transporters (as is 
recognised, for instance, for the solute carrier SLC22A4 and ergothioneine). This novel analysis casts an 
entirely different light on the kinds of natural molecules that are to be seen as most like marketed drugs, 
and hence potential transporter substrates, and further suggests that a renewed exploitation of natural 
products as drug scaffolds would be amply rewarded. 
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Introduction 
Given the overwhelming evidence [1-20] that pharmaceutical drugs must and do exploit endogenous 
transporters that normally transport biological metabolites, and that normally any diffusion of such drugs 
through the phospholipid bilayer portions of undamaged biological membranes is negligible [1, 3, 5-7, 10, 
11, 13, 21], we [2, 22-24] and others (e.g. [16, 25-30]) have been assessing the extent to which marketed 
(hence successful) xenobiotic drugs are similar in structural terms to endogenous human metabolites (that 
we sometimes refer to as ‘endogenites’). 
Chemical similarity is a slippery concept (see e.g. [31-35] and below) but, leaving aside descriptor-based 
vectors [36], it is most commonly assessed by encoding the molecules of interest into one or more 
fingerprints expressed as bitstrings, then comparing the bitstrings, again most commonly in terms of their 
Jaccard or Tanimoto similarity [37-39]. Our first detailed study [22] noted that the quantitative 
(Jaccard/Tanimoto) similarity varied markedly with the different (fingerprint-based) encodings used (and 
we reproduce the essential and Open Access findings in Figure 1A, below), just as does the appearance or 
otherwise of ‘activity cliffs’ [40-42]. To a certain degree, the shape of the profiles of rank-ordered drugs vs 
their Tanimoto similarity to the closest endogenous metabolite were smooth curves that differed 
somewhat. However, this of itself did not tell us – notwithstanding the numerical variation in Tanimoto 
similarity with each encoding – whether the rank order of individual drugs themselves was more or less 
well preserved for each encoding. In other words was the drug that was numerically most similar to an 
endogenite under the MACCS encoding also most similar under (say) the Atom Pair encoding?  
The Tanimoto similarity is a true metric, and while it returns a numerical value between 0 and 1 the 
question also arises as to which values of the Tanimoto similarity genuinely count as ‘significantly similar’ 
[34] from a utilitarian point of view. Unlike QSAR and other ‘supervised’ methods where there is an 
objective function, for which the predictions of the model can be tested on unseen data (e.g. where a 
Tanimoto similarity of 0.85 to a ‘hit’ in a drug discovery assay increases the chance of another hit by 30-fold 
[43]), the pure notion of chemical similarity is really an ‘unsupervised’ method, and its numerical value is 
simply that.  
Previously, apart from the addition of vitamins, we were rather restrictive about what might constitute 
an endogenous metabolite or ‘endogenite’, and we here recognise that this restriction was not only 
unnecessary but potentially very misleading, as any natural molecule with a high kcat or kcat/Km [44-47] for a 
particular transporter might reasonably be regarded as a ‘natural’ substrate for it. In particular, we may 
suppose that there are or have been natural, bioactive/psychoactive dietary and medicinal components 
(and their and other microbiome-derived products) that are both beneficial and common enough that the 
host has essentially been exposed to them more or less regularly through evolutionary time, albeit they do 
not appear in the common models of human metabolism. Since useful bioactivity in tissues implies uptake, 
natural selection would then ensure that we had actually evolved transporters for them, and that these 
molecules, despite not being synthesised by the host, are properly to be seen as ‘natural substrates’ of such 
transporters. L-ergothioneine is a particularly clear example of this.  
Some mammalian transporters with known selectivity for exogenous natural products 
L-ergothioneine (2-mercaptohistidine trimethylbetaine; IUPAC name (2S)-3-(2-Thioxo-2,3-dihydro-1H-
imidazol-4-yl)-2-(trimethylammonio)propanoate) is not synthesised by mammals, but exists in a wide range 
of foodstuffs (especially mushrooms) and may be highly concentrated in mammalian tissues [48, 49]. 
Several types of evidence imply that it has an important role in vivo as a natural antioxidant [50-52]. First 
this activity may be measured directly [53-55]. Secondly, decreasing it leads to the accumulation of the 
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products of the interaction of macromolecules with hydroxyl radicals [56-58] and a decreased lifespan in 
model organisms [59].  Thirdly, it acts as a cytoprotectant [48, 60-64]. Our interest in it here comes from 
the fact that it has been found to be the natural (or at least most active) substrate of the concentrative, 
Na+-dependent transporter SLC22A4 [65-67] (once referred to as OCTN1, now the ergothioneine 
transporter, which is also capable of transporting drugs such as the antidiabetic metformin [68]) (for SLC 
terminology see [69] and http://bioparadigms.org/). It was known that OCTN1 transported organic cations, 
but not what the ‘natural substrate’ might be. Thus, Gründemann and colleagues [65] incubated cells with 
and without recombinant OCTN1 transporter expression in paired assays with diluted plasma (taken to 
contain all candidate substrate molecules) and compared differences in the uptake of the various 
compounds by mass spectrometry. The first substance identified was proline betaine (stachydrine). 
Subsequent tests on structurally related molecules showed that ergothioneine was much the best 
substrate, with an uptake activity almost 100-fold higher than those for tetraethyl ammonium and carnitine 
[65] (that were previously believed to be the ‘main’ substrates), and that cells lacking the transporter were 
virtually impermeable to ergothioneine.  Since it does not seem to be essential for the growth of the host it 
has not attained the status of a vitamin, but it is clearly highly beneficial. (Its presence in almost all 
foodstuffs means that starvation for it specifically, the usual means of discovering or identifying a vitamin, 
has probably never occurred.) The same may generally be said to be true of other nutritionally beneficial 
molecules of plant origin, of which the flavonoids are among the best known.  
Indeed, in a similar way, it appears that specific transporters for flavonoid-type molecules also exist [70-
72], albeit their molecular taxonomy remains unclear [73]. This said, a transporter in plants [74] shows 
significant homology to bilitranslocase, a liver uptake transporter for blood-derived bilirubin, and 
bilitranslocase has been shown to transport dietary flavonoids [75], in particular anthocyanins [76-79]. Thus 
we are led to the view that we should consider as substrates for mammalian transporters not only the 
known intermediary metabolites, but also a variety of (mainly plant and microbial) dietary molecules that 
are bioactive and beneficial, even if not essential. This is because organisms will have coevolved with them 
for millions of years since ‘animals’ began to consume plants [80-83] and to harbour microbes [84, 85]. 
Even stronger natural selection may be expected since the time that such plants actually began to be 
utilised in agriculture [86] or prescribed for medical benefit [87, 88], as in Ayurvedic [89-91] and Chinese 
Herbal Medicine [90, 92, 93] (ca 5-8000y BP). If this is the case, we would expect to find even more 
structural similarities between drugs and such natural products when these are compared to drug-
endogenite similarities (and actually this proved to be the case in a pilot study; Figure 5C of [22]). One 
purpose of the present paper was to test this idea explicitly and in much more detail. Indeed, it transpires 
(see a detailed analysis in the body of this paper) that many of the least human-endogenite-like marketed 
drugs are considerably closer in structure to common plant and microbial secondary products than they are 
to endogenites. If we take the term ‘natural substrate’ to mean a substance to which an organism has been 
exposed and for which a transporter has a particularly high kcat or kcat/Km, it is reasonable to refer to such a 
molecule as a ‘natural substrate’, as in the ergothioneine/SLC22A4 example above. Another exogenous 
molecule that seems similarly valuable to mammals [94-105] and other organisms [106], albeit its uptake 
transporter is not yet known, is pyrroloquinoline quinone (PQQ) [107], also known as methoxatin, a redox 
cofactor normally associated with prokaryotes [108, 109].  
How similar is similar? 
Although the concept of what counts as ‘significantly similar’ must be recognised as highly important in 
cheminformatics, there has been surprisingly little work done on it; most of it has involved assessing the 
likelihood that a given similarity could be achieved from a (more or less random) distribution of chemicals 
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[34, 110-114]. Given that our original, underlying interest is in understanding those features of drug and 
endogenous metabolite structures that tend to determine whether a drug is closer to or far from being 
most similar to a specific endogenous (or other) metabolite, the question is important (but the distribution 
of chemical structures is far from random, one having been selected by natural evolution, the other via the 
processes of drug discovery). Thus, the first part of the present paper analyses that question. The 
conclusion is that the rank order is reasonably preserved for only a small fraction – some 5-10 % – of  those 
drugs that are most similar to an endogenite, but that for the vast majority of drugs not only the numerical 
value of the (Tanimoto) similarity but also the rank order depends very strongly indeed on the encoding 
used. However, the fraction of drugs for which different fingerprinting methods of encoding do give 
consensual answers (Tanimoto similarity ≥ 0.8, for instance) provides a defensible cut-off for what really 
counts as ‘significantly similar’. This leads to a second part, where we establish that plant- and microbially 
derived natural products have a much greater similarity to marketed drugs than do the endogenous 
metabolites of Recon2, and that they are in fact almost certainly the more common ‘natural’ substrates of 
the transporters on which pharmaceutical drugs hitchhike. This has profound implication for our 
understanding of the nature and evolution of human drug transporters. 
Experimental  
As previously [22-24, 115], we used the list of 1381 marketed drugs and 1113 Recon2-based 
endogenous metabolites as provided in the Supplementary information to [22]. A number of natural 
products and other databases exist [116-121]. We have here used the dataset for measured serum 
metabolites kindly provided by Prof David Wishart and colleagues [122], but removed all substances 
marked as drugs or that were in recon2. In addition, where noted, we also studied datasets such as UNPD 
http://pkuxxj.pku.edu.cn/UNPD/ [123] and ZINC [124, 125]. We also obtained a license for the 
(commercial) Dictionary of Natural Products [126] http://dnp.chemnetbase.com/intro/. All comparisons 
were done using KNIME-based workflows ([127-129] and www.knime.org/), and in particular we made use 
of the RDKit nodes [113, 130] (http://rdkit.org/).   
Results and Discussion 
Variance in ‘similarity’ with different fingerprint encodings 
Leaving aside molecules that are actually both drugs and metabolites, some drugs are clearly much 
more similar to one or more endogenous metabolites than are others, and this is true for a variety of 
fingerprint encodings [22-24] as provided via RDKit [113, 130]. The question thus arose as to whether these 
similarities extended to the actual rank orders of the drugs (with 1 always being the drug most similar to an 
endogenite). In other words, was the drug that was most similar to an endogenite when these were 
represented using the MACCS encoding also most similar with say the Atom Pair encoding? For ease of 
assessment, Figure 1A recapitulates the original analysis [22] (freely available under a CC-BY license). The 
three encodings that seemed to maximise the endogenite-likeness of marketed drugs in the earlier paper 
[22] were the MACCS, Layered and RDKit encodings in RDKit. Thus Figure 1B and 1C show, respectively, the 
relative rank orders of Layered and RDKit vs MACCS, all using Tanimoto as the metric of similarity. It is clear 
that while a small subset of the most endogenite-like drugs preserve their rank order between encodings, 
the rank order for the vast majority depends very strongly on the encoding used (cf. [113]). Also shown for 
Layered and RDKit (Figures 1B, 1C) are the names of a few drugs for which the differences in rank order are 
most extreme. The same kind of phenomena are true for Torsion vs MACCS (Figure 1D) and indeed for all 
the other comparisons tested (data not shown, but all of these data are provided as a spreadsheet via the 
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Supplementary information (DvsMDrugRanks_Full_w_descriptors_hits_with_MACCS_TS.xls)). Overall, while 
the generation of fingerprints is entirely deterministic, we could discern no real molecular properties that 
would predict which TS values for a given drug would be ‘high’ or ‘low’ for the set of endogenites. This 
could be seen as giving weight to view that each is of value and might be used as required. 
We also compared the Tversky similarities (=0.2, =0.8) (see [24, 115]) for the different encodings, 
with Figure 1E illustrating its comparison with the rank-ordered Tanimoto similarity for the MACCS 
encoding. It may again be concluded that while some drugs appear numerically similar to a given 
metabolite under the different metrics, many do not. However, in this case the correlation (r2 = 0.76) is 
considerably better than that for comparisons of the different encodings. Finally, we illustrate several 
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Figure 1. Cumulative similarity and rank order of various encodings. A. Cumulative rank order (most similar on the 
right) of a drug to its closest endogenite for a series of encodings, Redrawn (under a CC-BY license) from [22]. For the 
other parts of this figure, each symbol represents the rank order of the encodings specified. In addition, although 
there were no observable trends, symbol size encodes total polar surface area, while colour encodes the number of 
aromatic rings in the drug (0 blue, 1 emerald, 2 red, 3 yellow, 4 lilac, 5 orange, 6 sapphire, 8 cyan), and these can help 
to identify individual molecules in different encodings. B. Layered vs MACCS encoding, Tanimoto similarities, r
2
 = 0.38. 
C. RDKit vs MACCS encoding, Tanimoto similarities, r
2
 = 0.16. D. Torsion vs MACCS encoding, Tanimoto similarities, r
2
 = 
0.20. E. Tversky (=0.2, =0.8) similarity vs Tanimoto similarity for MACCS encoding. r
2
 = 0.76. F. Plot of multiple 
comparisons (blue best linear fit, red best LOESS fit). 
 
To encapsulate and to summarise all of the RDKit encodings used in one graph, we compared the sum of 
all the rank orders with their range (Figure 2A). Thus those at the top right of the plot (Figure 2B) are those 
drugs that are reliably of high rank order (most similar) whatever the encoding; there are only 44 where the 
cut-off was (somewhat arbitrarily) drawn. Similarly, a small subset are reliably of low rank order whatever 
the encoding (and include in particular ‘drugs’ such as fluorinated inhalational anaesthetics that are clearly 
very far from endogenites) (Figure 2B). Another subset (arbitrarily picked and illustrated in Figure 2C) 
contains drugs that are mainly not seen as very endogenite-like except in one or two encodings. However, it 
is obvious that for the vast majority of other drugs the rank order (and hence endogenite-likeness) depends 
very strongly upon the exact encoding used. For these, endogenite-likeness is not therefore a property of 
the drug per se but additionally (even particularly) of its encoding into whichever fingerprint is chosen. By 
contrast, the top 10 % or so of drugs, that are within a MACCS Tanimoto similarity of ~0.8 to at least one 
endogenite, are relatively robust to the different encodings (Figure 2D), and one could argue that this 
relative independence from the nature of the encoding does seem to be a good metric of “similarity”. 
Although this is something of a self-fulfilling prophecy, inspection of those drugs also clearly does show a 
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metabolite-likeness, especially to endogenites such as nucleobases and sterols (Figure 2E). In a similar vein, 
although individual encodings can vary significantly, there is a good correlation between the average 
Tanimoto similarity (for the Morgan, FeatMorgan, AtomPair, Torsion, RDKit, Avalon, Layered, MACCS and 
Pattern encodings in RDKit) and the drugs that have a Tanimoto similarity ≥ 0.8 in the MACCS encoding (our 
standard benchmark) (Figure 2F). In Figure 2F, the overall correlation (r2) = 0.77 (slope = 0.75), and the 
variance is much less than that of the rank order. 
Choosing the closest encoding for each comparison 
Inspection of figures 2A-2C shows a very considerable range for the majority of molecules, implying that 
for each molecule there is at least one encoding that is seen as having an especially close value of the 
Tanimoto similarity for a particular drug-endogenite pair.  This best or largest value is here referred to as 
the Take Your Pick Improved Cheminformatic Analytical Likeness or TYPICAL encoding/similarity. Figure 2G 
shows a heatmap of the similarities of drugs and metabolites using the TYPICAL encoding (four molecules 
are dropped because of a curiosity with the Torsion encoding). Under these circumstances, the percentages 
of drugs having a TYPICAL similarity to an endogenite of 0.8, 0.75 and 0.7 are, respectively, 45 %, 66 % and 
88 %, as may also be observed in the cumulative plot of Figure 2G shown in Figure 2H. Finally, Figure 2I 
shows evidence that a suitable cut-off value of TS with a standard encoding for ‘genuine similarity’ is in the 
range 0.75-0.8. 
Use of the maximum common substructure 
Another means of comparing structural similarities (and hence rank orders), and one that does not 
depend nearly as much (but see [131]) on the fingerprint encoding used, is according to the size of their 
maximum common substructure (MCS). As before [24], we have here done this using a series of values of 
the Tversky similarity, varying the Tversky similarity parameters (and ) such that their sum was either 1 
(Figure 3A) or 2 (Figure 3B). Since the encoding is the same, the correlations between the rank orders for 
different values of and  are much higher than for the different encodings, with a clear trend of 
similarities being visible in the violin plot of Figure 3C. Finally, here, we illustrate a comparison of the MCS 
with a Dice coefficient (=  = 0.5) and the MACCS_Tanimoto; again for the drugs with the highest values 
of TS to a metabolite (we illustrate those over 0.85 this time) there is a clear consistency of the metabolite-
likeness of their fingerprint-based MACCS encoding and their MCS with a Tversky similarity. 
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Figure 2. Relationship between the sum and the range of the rank order of the different encodings. A. Overview of the 
shape of the plot. B. names of marketed drugs that are reliably most or least like an endogenite whatever the 
encoding. C. Names of drugs for which there is at least one reasonably high rank order but for which mostly they are 
not encoded as that endogenite-like. D. Names of top 138 drugs (for which TS ≥ 0.8) judged by MACCS similarity in 
rank order. E. Names of metabolites most similar to the most metabolite-similar 138 drugs (for which TS ≥ 0.8) as 
judged by MACCS similarity. F. Average value of TS for multiple encodings vs MACCS-encoded Tanimoto similarity. G. 
Heatmap of similarities of drugs vs endogenites using the TYPICAL encoding. H. Cumulative plot of heatmap data of G. 
I. Evidence that 0.75-0.8 is a suitable cut-off value of TS for ‘genuine’ similarity. 
 
Assessment of contribution of descriptors to rank orders using random forest regression 
In order to understand the structural bases for some of the rank orders, we set up a random forest 
regression (see e.g. [132, 133]) to assess whether we can indeed predict the rank of a particular drug 
molecule in terms of the Tanimoto similarity of its closest endogenous metabolite. As this is a supervised 
method, we trained on a subset of examples to see if we can predict an out-of-the-box set. The results are 
shown in Figure 4A, indicating a reasonable degree of success. To ensure that this was not due to any kind 
of overtraining, we performed target permutation i.e. we randomised statistically the values of the target 
column one thousand times (data not shown). This served to break any true correlations between the 
features and the targets, showing that the observed correlations were indeed real. Figure 4B shows an 
equivalent permutation on the features (i.e. the RDKit descriptors), to assess those which most contributed 
to the observed correlations. Finally, Figure 4C shows the improvement in correlation that was observed (in 
out-of-the-box data) as the number of features was increased; evidently ten features were sufficient to 
achieve the maximum correlation observed. 
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Figure 3. Rank order of drug-endogenite similarities as judged by the size of their maximum common 
substructures (MCS), for varying values of the Tversky similarities (and). A. Sum of and= 1. B. Sum of 
and=  2. C. distribution of values of the MCS for varying values of Sum of andwhen their sum is 2. D. 
MCS Dice coefficient against MACCS Tanimoto similarity. 
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Figure 4. Random forest regression of RDKit features on the rank order prediction of the Tanimoto similarity of a 
given drug molecule, using the RDKit fingerprint encoding (a graph-based method that should not of itself be related 
to physicochemical descriptors) and the Tanimoto similarity. A. Predicted against actual. B. Ranked order of relevant 
features. C. Stepwise improvement in regression as features are added in the order of those seen in B. 
How similar are drugs to dietary and medicinal natural products from plants and microbes? 
As mentioned in the introduction, and leaving aside molecules that are actually both drugs and 
metabolites, some drugs are clearly much more similar to one or more endogenous metabolites than are 
others, and this is true for a variety of fingerprint encodings [22]. One question that we have not previously 
asked is about how much better our ‘similarities’ might be if we also used dietary or bioactive molecules 
that are not in Recon2. Specifically, including for evolutionary reasons rehearsed in the introduction, the 
question thus arose as to whether these similarities could be increased, especially for the “less similar” 
drugs, when we began to include bacterial, plant, and fungus-derived secondary metabolites.  
We recognise that we must, so far as is reasonable, compare like with like, and certainly it can always be 
claimed that there is a greater likelihood of finding a molecule with a greater similarity (in a given encoding) 
as the size of a database is increased per se. The normal way of dealing with this is simply to quantify the 
likelihood that a given similarity could be achieved from a (more or less random) distribution of chemicals 
taken from that database [34, 110-114]. This is not entirely logical from a biological point of view, however, 
since such samples are not (from) a random distribution but are the products of evolutionary selection. 
Thus we prefer other arguments, based on comparing biologically relevant databases. We do, however, 
also recognise that the gross distribution of properties such as MW, log P, total polar surface area (TPSA) 
and so on differs between the different databases, and we will need to ensure that this is not a trivial cause 
of any differences observed. Thus in some cases we used the MatchIt algorithm [134, 135] (and its 
attendant R code) to select subsets from the various databases with the same distributions of properties as 
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those of endogenites.  
The “Universal Natural Products Database” (UNPD) (http://pkuxxj.pku.edu.cn/UNPD) is said [123] to be 
the largest noncommercial and freely available database for natural products. At the time of its original 
publication [123] UNPD comprised 197,201 natural products from plants, animals and microorganisms. Our 
first task here involved regularising or ‘cleaning’ the UNPD for our purposes. Cleaning was perfomed using a 
KNIME workflow and lowered the number of molecules included from the ca 229,000 initially logged when 
we downloaded it in December 2016 to 155,048. The main ‘loss’ was due to the loss of (what we could not 
deconvolve as) duplicates. Some of these may have been stereoisomers, but the 2D connection table 
provided contained no stereochemistry. Figure 5 shows the distributions of four properties between the 
endogenous metabolites of Recon2 and the contents [123] of the ‘cleaned’ UNPD natural products 
database. Although there are clear differences, they are in fact surprisingly similar (see also [22, 123]), and 
as noted above, individual descriptors had only a minor influence on the random forest model.  
We next (Figure 6A) compared the ordered results of the Tanimoto similarity of the various marketed 
drugs to those of the nearest representative in our ‘cleaned’ version of UNPD. The results are absolutely 
striking; while 90 % of marketed drugs had an endogenite with a TS > 0.5, the corresponding value for 
UNPD of 90 % was a TS of 0.7. Table 1 shows the %age of drugs with a closest molecule with a TS exceeding 
various values (MACCS encoding) for endogenites and UNPD library members. Fairly obviously, the chance 
of finding a close homologue is massively greater (often four-fold or more) for the latter, especially for TS 
values greater than about 0.7.  
 
Figure 5. Distribution of four properties between the endogenous metabolites of Recon 2 [136] and the 
cleaned version of UNPD [123]. The original UNPD file as downloaded contained 229,358 molecules. 
‘Cleaning’ removed duplicates as well as molecules that were in either Recon2 or in the list of marketed 
drugs, both of which were precisely as described and used previously [22-24]. The resulting spreadsheet 
retained resulted in a total of 155,048 molecules. The smoothed version is the probability density as derived 
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Figure 6. Relationship between the normalised rank order of the nearest database molecule to marketed drugs for 
(red) the cleaned version of UNPD [123] and (blue) Recon2. ‘Cleaning’ removed duplicates as well as molecules 
that were in either Recon2 or in the list of marketed drugs, both of which were precisely as described and used 
previously [22-24]. A. Full, cleaned version of UNPD. B. A sampled version of UNPD using the same number of 
molecules as those in Recon2 sampled as per the distributions in Figure 5. 
Table 1. Tabulation of data from Figure 6A. 
TS > at least Drugs/endogenites (% drugs) Drugs/UNPD (% drugs) 
0.5 1185 (85.8 %) 1375   (99.6 %) 
0.55 941   (68.1 %) 1368   (99.1 %) 
0.6 708   (51.3 %) 1339   (97.0 %) 
0.65 486   (35.2 %) 1289   (93.3 %) 
0.7 322   (23.3 %) 1113   (80.6 %) 
0.75 201   (14.6 %) 830     (60.1 %) 
0.8 138   (10.0 %) 614     (44.5 %) 
0.85 93     (6.7 %) 447     (32.4 %) 
0.9 53     (3.8 %) 314     (22.7 %) 
 
One obvious point is that the number of molecules in the cleaned UNPD is roughly 100x greater than the 
number of those in Recon2, so it could be argued that this alone means statistically that there is simply a 
greater likelihood of finding a ‘closer’ molecule. While true, this ignores the biology (and the fact is that we 
did find massively more structurally close natural products than endogenites for a given drug), but we 
report both analyses. Thus, Figure 6B shows the same comparison as that of Figure 6A save that the UNPD 
molecules are sampled so as to be numerically equal to those of Recon2, and to share its distribution of the 
four molecular properties shown in Figure 1. In this case, the ‘advantage’ of UNPD is clearly diminished, 
albeit still substantial, with 70, 124, 197, 282 and 417 molecules with a TS > 0.9, 0.85, 0.8, 0.75 and 0.7 for 
UNPD, but only 57, 93, 130, 209 and 329 equivalently for Recon2. Thus for some values of TS, UNPD can 
enjoy a 50 % advantage over Recon2 even when comparisons are strictly scaled to numbers, whatever the 
biology. We also ran the sampled version multiple times, to look at the ‘range’, but the numbers involved 
were great enough that this made negligible difference. Note that Recon2 does not contain the thousands 
of permutations of triglycerides and the like [137], that would increase its size substantially but not provide 
significantly better hits (i.e. the ‘100x’ figure above is rather a substantial overestimate of the differences in 
true size), and we also know of many more endogenites that are not yet in Recon2 (see e.g. [9]). 
Figure 7A shows a similar comparison for the natural products in a cleaned-up version (see Materials 
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and Methods) of the Dictionary of Natural Products (DNP) [126], seen as a fair comparison [138], and again 
using the MACCS encoding. Our cleaned DNP (with marketed drugs, endogenites and duplicates removed) 
contains 72,442 molecules, including 32,390 that are already in UNPD (implying 41,228 that are ‘new’, but 
also implying 123,443 that are in our UNPD but not in our DNP). Here there are at least 37 % of drugs that 
have a TS greater than 0.8 to the nearest database member, and 50 % have a TS greater than 0.75, 
contrasting with values for Recon2 of just 10 % and 15 %, respectively. These findings are roughly similar to 
(but the similarities slightly lower than) those from UNPD, indicating that at least some ‘winners’ are unique 
to UNPD and some to DNP. In a similar vein, Figure 7B shows the sampled version, with little impact. 
  
Figure 7. Relationship between the normalised rank order of the nearest database molecule to marketed drugs for 
(red) the cleaned version of the Dictionary of Natural Products (DNP) [126] and (blue) Recon2. ‘Cleaning’ removed 
duplicates as well as molecules that were in either Recon2 or in the list of marketed drugs, both of which were 
precisely as described and used previously [22-24]. A. Full, cleaned version of DNP. B. A sampled version of DNP 
using the same number of molecules as those in Recon2 sampled as per the distribution of the properties in Figure 
5. 
Figure 8 shows the effects of cleaning and the degree of overlap of molecules in our cleaned versions of 
UNPD and DNP.  
 
Figure 8. Overlaps between UNPD and DNP databases. ‘Cleaning’ removed duplicates as well as molecules 
that were in either Recon2 or in the list of marketed drugs, both of which were precisely as described and 
used previously [22-24].  
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The ZINC database [124] includes a very large number (ca 16M) and variety of synthetic molecules. As 
usual, we cleaned it to remove any molecules that were marketed drugs or Recon 2 metabolites, and ran it 
(and recon 2) against drugs as above. This time we ran it as 50 subsets, each of some 148,000, to show the 
range of curves that we could get. Thus the percentage of ZINC samples that had a member that was within 
a TS of 0.8 to drugs is between 35 and 45 % depending on the sample, while that for a TS of 0.75 or greater 
varied from 0.59 to 0.74. This implies a considerably greater variation than that for the natural products. 
 
Figure 9. ZINC database. Relationship between the normalised rank order of the nearest database molecule 
to marketed drugs for the ZINC database (ZINC) [124] (red) and Recon 2 (blue). The ZINC database was 
‘cleaned’ to remove molecules that were in either Recon2 or in the list of marketed drugs. 
Another source of candidate transporter substrates was the list of molecules observed in serum as 
catalogued at http://www.serummetabolome.ca/, on the grounds that if they had reached the 
bloodstream they must have been transported there. We produced a version of this that again lacked all 
marketed drugs and recon2 metabolites, amounting to some 1480 molecules. Inspection of these indicated 
that they were mainly nutrients and their metabolites, along with the metabolites of various medicines. Of 
course what is in serum largely reflects what was recently ingested, and so it can hardly be expected to 
include all the natural products listed in UNPD and DNP. The curves are shown for both the subset 
normalized to the size of recon 2 (Figure 10A) and the full set (Figure 1B). Clearly, again, there are a 
significant number of ‘serum’ molecules that are not in Recon2 yet are structurally closer to drugs.  A 
detailed analysis beyond this is not particularly pointful, since clearly what is in serum reflects recent 
ingestion only, and this is only a small subset of the contents of UNPD and DNP (Figure 10C). 
The union of the UNPD and DNP databases 
Since there was (surprisingly) little overlap in the contents of the ‘cleaned’ versions of UNPD and DNP 
(Figures 8, 10C), it was of especial interest to run the analysis on their union, a set of some 195,285 
molecules. The results are shown in Figure 11A for the full set for the MACCS rank order and Tanimoto 
similarities, and for each of the standard RDKit encodings in Figure 11B for a 148k subset. The results 
(Figure 11A,B) are absolutely striking: for the MACCS encoding, 45 %, 60 % and 80 % of marketed drugs are 
within a TS of 0.8, 0.75 and 0.7 to at least one inhabitant of the union of the UNPD and DNP databases, 
regardless of the inclusion of recon2 metabolites. Figure 11C shows the data for the multiple encodings. On 
this basis, 80 % of all drugs are within a TS of 0.8 of a natural product for the Patterned encoding, and 
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almost all the ‘missing’ molecules with similarities above say 0.75 are natural products. This becomes even 
clearer in Figure 11D, where we chose the TYPICAL encoding, i.e. that which maximises the TS between a 
drug and a comparator molecule, regardless of the encoding, and performed this on the full combined 
natural proucts dataset of ~196,000 molecules. The result was that 92 %, 98 % and 99.5 % are within a TS of 
a natural product of 0.9, 0.85 and 0.8, respectively. Figure 11E shows the rather widespread distribution of 
‘winning’ similarities between the different encodings. Each is represented at least once, and, interestingly 
(as is also clear from Figure 11C), ‘patterned’ is the most common. This is a more recent addition to the 
RDKit stable, and was not available when the comparison in Figure 1 was done [22]. However, the next 
most used are RDKit, MACCS, Layered, and Morgan; with the exception of the latter, the same may also be 
inferred from the endogenite-only data in Figure 1. There were exactly 500 occasions on which at least one 
endogenite was the closest in at least one encoding. However, when the TYPICAL encoding used, each of 
the 1381 drugs was closer to (or equal with) at least one exogenous natural product that is in either or both 
of UNPD and DNP than it is to an endogenite (data not shown). Finally, in previous work [15], we had 
compared a meta-analysis of 680 Caco-2 cell permeabilities of 187 marketed drugs with their endogenite-
likeness (finding none). Neither did we find any relationship between Caco-2 permeability and any analysis 
of closeness to the union of the UNPD and DNP databases; as an illustration, Figure 11F compares the same 
permeabilities with the maximum pattern TS. Clearly any causal relationship that may exist is overwhelmed 




Figure 10. Human serum metabolome. Relationship between the normalised rank order of the nearest molecule to 
marketed drugs for the ‘human serum metabolome’ database [122] (green) and Recon 2 (blue). The human serum 
metabolome database was ‘cleaned’ to remove molecules that were in either Recon2 or in the list of marketed 
drugs. A. Sampled subset to be the same size and property distribution as that of recon2. B. Full set of ‘human 
serum metabolome’ molecules after cleaning. C. Venn diagram of the co-distributions of molecules in the cleaned 
versions of UNPD, DNP and the human serum metabolome databases. 
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Figure 11. A. Relationship between the normalised rank order of the nearest molecule to marketed drugs for the 
union of the UNPD and DNP natural products databases (green) and Recon 2 (blue). The UNPD and DNP databases 
were ‘cleaned’ to remove molecules that were in either Recon2 or in the list of marketed drugs. B. Similar data plotted 
for a 148k normalised subset, also lacking marketed drugs. C. The same, for each of the standard RDKit encodings. D. 
The same for the TYPICAL encoding. E. Distribution of encodings used in the winning molecules that contributed to the 
TYPICAL encoding (the encodings are named according to those provided in RDKit as part of the KNIME environment). 
F. Lack of relationship between Caco-2 permeability and maximum TS of the union of the UNPD and DNP databases 
using the pattern encoding (slope = -1.02, r
2
 = 0.011. Drugs are coloured according to the encoding with the largest TS. 
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Discussion 
Different similarities from different encodings 
As we continue to analyse the structural ‘similarities’ of drugs and endogenites in different ways [14, 15, 
22-24, 115], it is becoming increasingly clear that a given drug-endogenite pair can have a highly variable 
numerical similarity depending on which fingerprint encoding or metric of similarity is used. In the present 
work, we extend this recognition to the fact that – apart from a very small subset of ‘reliably’ endogenite-
similar drugs – the degree of similarity and its rank order can be dominated by the encoding used. This was 
largely not the case in the analysis of Riniker and Landrum [113], who compared the similarity of 
fingerprints of larger and very different datasets of library compounds. We also noted that we could predict 
the rank order using random forest regression, so it was, as expected, a deterministic property. 
Willett and colleagues have suggested that ‘fusing’ the results of different fingerprint encodings may 
give more robust analyses [139-145]. Our strategy is somewhat similar in that we recognise the highly 
variable rank orders (and Tanimoto similarities) that result from the different encodings, such that their 
variance tends to increase with their mean rank order. Summing (equivalently, averaging) the rank orders 
(see also [139, 145]) was a particularly convenient means of combining the data. When this was done, there 
was a clear trend to the effect that there was much less variance among those molecules with the most 
reliably high rank order (numerically small values), leading to a conclusion that for Tanimoto similarity 
values over ~0.75 or 0.8 the similarities are fairly robust to the specific encoding used, and on that basis 
may reasonably be considered ‘reliable’ or ‘significant’. This said, there was often at least one encoding for 
which the TS between a given drug and at least one endogenite exceeded 0.75, such that taking the 
maximum of these regardless of the encoding did increase the number of ‘similar’ endogenites. 
Unfortunately, with occasional exceptions [146, 147], our knowledge of the substrate specificities of 
individual transporters is inadequate to the task of assessing whether the ‘nearest’ (or a nearby) metabolite 
is actually the ‘natural’ or endogenous substrate [12]; by and large, that will have to await further 
experimentation [12].  
Natural products that are nutrients or bioactive drugs must necessarily be transported 
As was recognized from its inception [148], the ‘rule of 5’ [148-154] is taken not to apply to large, 
natural products, and also does not apply if transporters are involved in the uptake. Natural products have 
been and remain a major source of successful (marketed) pharmaceutical drugs [155-162], Indeed, about 
one half of new drugs are based closely on natural products [157, 158], and many transporters exist for 
them [163-166]. 
It is to be assumed that anything that is of eventual benefit to (the reproductive fitness of) an organism 
is likely to be a subject of natural selection and adaptive evolution, even in the laboratory [167], in vitro 
[168], and in silico [169]. Thus, if the eating by a mammal of say a plant or fungus has beneficial properties 
in terms of improving the mammal’s reproductive longevity, selection will act to enhance the uptake of the 
bioactive principles, at least to a non-toxic level. Certainly, as mentioned, it is well established that natural 
products themselves contribute importantly to the development of successful drugs (e.g. [155-157, 159-
162, 170-173]). Consequently it is clear that a or the ‘natural’ substrate of at least some transporters is in 
fact likely to be an exogenous molecule that imparts health benefits, and ergothioneine and its uptake by 
SLC22A4 seem to provide a very clear example [49, 50, 59, 65, 66].  
The acquisition of the ability to maintain lactase into adulthood (hence to tolerate lactose and dairy 
products) is highly heterogeneous and of recent evolutionary origin (~5000y BP [174-178]). Similarly, the 
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actual human selection and prescription of plants as medications is of similar vintage [89, 91-93], albeit 
hominids and their evolutionary predecessors have been eating plants and fungi for many more millennia 
(angiosperms appear 50-100My ago). Hence, while it is not possible to replay the evolutionary tape, it is 
entirely reasonable that many of the several hundred human uptake transporters [69] were in fact 
selected, at least in part, precisely to transport exogenous secondary metabolites. Indeed, mammalian 
transporters are well known for their ability to transport many exogenous natural product drugs, e.g., SLCO 
family members for penicillins [179, 180], cephalosporins [181, 182], tetracycline [183], caffeine, 
theobromine and theophylline  [184] and digoxin [185], SLC22 for berberine [186] and protoberberines 
[187], morphine [188], erythromycin [189] and theophylline [189], SLC15 for penicillins and cephalosporins 
[190, 191], SLC6 family (norepinephrine transporters) [192] for ephedrine derivatives [193], and SLC36 for 
arecaidine (an active constituent of the Areca nut, often wrongly referred to as the betel nut) [194].  
Of necessity, there are transporters for exogenous natural products that serve as vitamins, such as 
ascorbate (SLC23 family [195, 196]), folate (SLC19 and SLC46 [197-199]), biotin and pantothenate (SLC5 
[200]), nicotinate [201], thiamine (SLC19 and SLCO [202-205]), and riboflavin (SLC52 [206-210]). 
In other cases the role of human protein transporters of natural products is well established, but their 
molecular nature (i.e. identity) has not yet been determined, e.g. those for psychoactive alkaloids such as 
cocaine [211] and nicotine [212-216] and opioids [217, 218]. Of course many transporters are known in the 
producer plants themselves [163-165]. 
Following this logic, the prediction, as tested here, is that at least some successful marketed drugs 
should be much closer to these plant and microbial molecules in structural terms than are the intermediary 
metabolites that are part of Recon2. The prediction was amply demonstrated, and serves to account for 
the otherwise anomalous finding that only a rather small fraction of intermediary human metabolites are 
reliably ‘similar’ (using the MACCS/TS metric) to marketed drugs at the level of 0.75 or 0.8. However, by 
contrast, we find that as many as 80 % of natural products show such a similarity when surveyed 
extensively.  This is consistent with the earlier, pilot findings (Figure 5C of [22]), and with the fact that Caco-
2 permeability was poorly correlated with (the MACCS encoding of) endogenite-likeness [15]. 
Evolutionary aspects of ‘secondary metabolites’ and other natural products 
The question of what roles might be played by secondary metabolites in evolutionary terms is an old 
one, and almost certainly does not have a unitary answer. Note that the original definition of ‘secondary 
metabolites’ was to the effect that only a small number of organisms made a given such molecule [219]. 
However, most of this literature on secondary metabolites, taken as virtually synonymous with ‘natural 
products’, focuses on the benefits to be gained by the producer organisms themselves. To this end, there is 
abundant evidence that at least some natural products are used as signals by (and towards) other 
individuals of the same species, and are thus pheromones [220]. Necessarily, evolutionarily early variants of 
natural products may lack potency at the concentrations expressed [221] and the fact that the wider the 
number produced, the greater the likelihood of their selection [222] can explain why the selection pressure, 
in terms of benefitting the producer, may often be quite modest. However, our focus here is on the 
benefits to consumer organisms. 
 It now seems clear that our earlier focus [22-24, 115] on transporters just of human-encoded 
intermediary metabolites as the potential source of the ‘natural’ substrates of the transporters on which 
pharmaceutical drugs hitchhike was somewhat misplaced. This is because humans, and at least their 
vertebrate (and indeed invertebrate) evolutionary predecessors, have been exposed for millions of years to 
plant- and microbe-based dietary substances that had bioactivities of various kinds, many of which must 
ADMET & DMPK 5(2) (2017) 85-125 Exogenous natural products as ‘natural’ drug transporter substrates 
doi: 10.5599/admet.5.2.376 113 
have been beneficial and thus conferred a selective advantage, however small [223, 224], on the host.  The 
origins of this remain uncertain, but the early ones (ca 1.8Gy BP) may have involved simple engulfment 
[225], with major eukaryote diversity set in place by 800My BP [226]. Even if one considers only 
angiosperms as potential sources of nutrients, these begin to arise ca 133 My BP [227] (with Solanaceae at 
around half that period BP [228]). Thus, the need (and ability) to take up plant and microbial metabolites is 
likely a trait of rather ancient origin. 
Transporter phylogenetics 
Transporter phylogenetics is an area that is still highly under-researched [229] (as are transporters in 
general [12]), and indeed nearly 100 new families are introduced into the Transporter Classification 
Database (TCDB) every year [230]. This is not the place to pursue that issue in detail, so a single example 
will suffice: a BLAST search of the sequence for human SLC22A4, the ergothioneine transporter, reveals 
(data not shown) that it is widespread among modern mammals, but obvious homologues are not to be 
found in reptiles, fishes, or lower taxa. We also note here that we have confined our thinking here to 
‘uptake’ transporters of the SLC families, and not discussed the ABC families mainly involved in efflux (e.g. 
[231-234]).  We have also ignored completely the highly heterogeneous tissue distributions of the different 
transporters (e.g. [235, 236]). Future work will benefit from incorporation of both these features. 
Drugs and natural products 
It is, of course, well known that many natural products can serve as medicines [88, 237], and that many 
purified substances derived therefrom are the basis of a significant fraction – probably 35-60 % depending 
on how one counts – of marketed drugs (see above, and [158, 238-240]). We think that the present work 
highlights even more clearly how important natural products and their derivatives are likely to be in terms 
of producing novel, safe and efficacious drugs. 
Conclusions 
The present analysis takes forward our continuing analysis of the structural similarities between 
marketed drugs and naturally occurring substances in two major ways. First, by looking at rank orders of 
similarities between encodings, we find very major differences, such that the metabolite with the closest TS 
to a drug in one encoding may be very different in both nature and TS value from that when compared with 
another encoding. There is no encoding that seems to us to have any special intellectual privileges, and as 
stressed by Everitt [241] unsupervised analyses should anyway best be judged simply on their utility. On 
this basis, we consider it entirely legitimate to pick and choose encodings to maximise apparent similarities, 
as a guide to testing, for instance, which other substances are competing substrates for the transport of a 
particular drug. 
Previously, we focussed solely on human endogenites and the contents of Recon2 when making these 
comparisons. However, not least because of the discovery by Gründemann and colleagues [65, 66] that 
SLC22A4 is in fact an ergothioneine transporter, we now recognise that we should include all kinds of plant- 
and microbial (and any other) natural products to which humans might have been exposed in evolution, 
and transport of whose bioactive principles might have been selected adaptively on the basis of their 
nutritional or medicinal activities and benefits. Clearly, natural evolution may be expected to have selected 
for the ability to transport molecules that in kind and amount were of benefit to the host. When we include 
such natural products, we find that the closeness of at least one of them, using one or more encodings, to 
marketed drugs is increased massively. This at once hereby points us at substances that might be the 
‘natural’ substrates of a given drug transporter, suggests molecules for QSAR studies thereon, and 
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potentially provides novel scaffolds for pharmaceutical drug discovery.  
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